Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided a year-end 2017 corporate review and announced clinical progress for two of its development programs: ThermoDox®, a proprietary, heat-activated liposomal encapsulation of doxorubicin, which is in Phase III development for treatment of primary liver cancer; and GEN-1, an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein, and which is in Phase I development for the localized treatment of ovarian cancer.
As quoted in the update:

“In 2017, Celsion achieved our key development goals for our two lead programs, ThermoDox® and GEN-1. We expect to build upon this success in 2018 as we work toward advancing our pipeline of clinical and preclinical development programs, which hold the potential to enhance the power of proven chemotherapy and immunotherapy platforms,” stated Michael H. Tardugno, Celsion’s chairman, president and chief executive officer.

Click here to read the full update and 2018 outlook.